Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...

Redburn Atlantic initiated coverage of Alnylam with a Buy rating and $353 price target Therapeutic options for patients with transthyretin ...

Alnylam already markets the medicine for people with a form of the condition that affects the nerves, but has long looked to an approval in cardiomyopathy as the kind of revenue driver that can ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

Analysts see drug as potential new standard of care in ATTR-CM Label includes benefit of reducing urgent heart failure visits March 21 (Reuters) - Alnylam Pharmaceuticals' (ALNY.O), opens new tab ...

Alnylam reported product revenue of $420 million in the third quarter of 2024, in line with analyst expectations. The company has reiterated its guidance for 2024, projecting total product revenue ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Siemens Healthineers AG (SEMHF – Research ...

Alnylam Pharmaceuticals saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its leadership in ...

Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major milestone — finally reaching profitability. Alnylam Pharmaceuticals ...